The Division of AIDS (DAIDS) was formed in 1986 to develop and implement the national research agenda to address the HIV/AIDS epidemic. Toward that end, the Division supports a global research portfolio on HIV/AIDS, its related co-infections, and co-morbidities. With the ultimate goal of creating an “AIDS-free Generation,” the Division continually develops and supports the research infrastructure and scientific expertise needed to enable innovative approaches aimed at: 1) halting the spread of HIV through effective and acceptable prevention strategies and a preventive vaccine; 2) treating and curing HIV infection; 3) establishing treatment and prevention strategies for the HIV co-infections and co-morbidities of greatest significance; and 4) partnering with scientific and community stakeholders to implement effective interventions.
Large-Scale HIV Vaccine Trial to Launch in South Africa | see Q&A—May 18, 2016
NIH Statement on HIV Vaccine Awareness Day—May 18, 2016
Media Availability: Single Antibody Infusions Provide Durable Protection Against HIV-Like Virus in Monkeys—April 27, 2016
Media Availability: Animal Study Paints Picture of the Earliest Immune Responses to HIV—April 13, 2016
NIH Launches Large Clinical Trials of Antibody-Based HIV Prevention | Q&A—April 7, 2016
Last Updated May 18, 2016